84594-95-6

Basic information

• Product Name: Iguratimod Impurity 5
• Synonyms: Iguratimod Impurity 5;4-methoxy-2-nitro-1-phenoxybenzene
• CAS NO: 84594-95-6
• Molecular Formula: C₁₃H₁₁NO₄
• Molecular Weight: 245.23074
• Mol File: 84594-95-6.mol

Chemical Properties

• Melting Point: 35 °C(Solv: methanol (67-56-1))
• Boiling Point: 162-165 °C(Press: 0.5 Torr)
• Appearance: /
• Density: 1.252±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Iguratimod Impurity 5(CAS DataBase Reference)
• NIST Chemistry Reference: Iguratimod Impurity 5(84594-95-6)
• EPA Substance Registry System: Iguratimod Impurity 5(84594-95-6)

Safety Data

• Hazardous Substances Data: 84594-95-6(Hazardous Substances Data)

Upstream product

• 5344-78-5 4-bromo-3-nitroanizole 
• 100-67-4 potassium phenolate 
• 12775-96-1 copper 
• 108-95-2 phenol 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 

Downstream Products

• 102077-92-9 4',5-Dimethoxy-2-phenoxy-diphenyl-ether 
• 105904-57-2 2-Brom-4-methoxy-diphenylaether 
• 1655-69-2 1-methoxy-4-phenoxy-benzene 
• 76838-31-8 1-Benzoyl-3-(5-hydroxy-2-phenoxy-phenyl)-thiourea 
• 76841-06-0 3-(Imidazolidin-2-ylideneamino)-4-phenoxy-phenol 
• 76839-11-7 (5-Hydroxy-2-phenoxy-phenyl)-thiourea 
• 149436-41-9 α-amino-2-methoxy-4-methanesulfonamido-5-phenoxyacetophenone hydrochloride 
• 123664-55-1 ethyl 2-(2-benzyloxy-4-methylsulfonylamino-5-phenoxybenzoyl)acetate 
• 123664-56-2 ethyl 3-[2-hydroxy-4-[(methylsulfonyl)amino]-5-phenoxyphenyl]-3-oxopropanoate 
• 123663-68-3 ethyl 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-3-chromenecarboxylate 
• 123664-66-4 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one-2-carboxylic acid azide 
• 123663-74-1 2-ethoxycarbonyl-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 

Relevant articles and documents

COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

Pd-Catalyzed Denitrative Intramolecular C-H Arylation

A Pd-catalyzed intramolecular C-H arylation of nitroarenes has been developed. Nitroarenes bearing tethered aryl groups at the ortho-position can be readily prepared in one step from 2-halonitroarenes by a nucleophilic aromatic substitution (SNAr). Under Pd/BrettPhos catalysis, activations of the C-NO2 bond as well as the C-H bond on arenes generated the corresponding biaryl linkage in moderate to excellent yields.

Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3- nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3- formylamino derivative (19a) and its 2'-fluoro and 2',4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1 mg/kg/d for 7 d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.

1-,2-,3-,4-,5-,6-,7-,8- AND/OR 9 SUBSTITUTED DIBENZOXAZEPINE COMPOUDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PAIN

The present invention provides substituted dibenzoxazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.